Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Rating of “Moderate Buy” by Brokerages
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year […]
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year […]
